Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The use of pramipexole in Parkinson's disease: are its actions D-3 mediated?
Autore:
Guttman, M; Jaskolka, J;
Indirizzi:
Univ Toronto, Natl Parkinson Fdn Ctr Excellence, Div Neurol, Dept Med, Toronto, ON, Canada Univ Toronto Toronto ON Canada Div Neurol, Dept Med, Toronto, ON, Canada Univ Toronto, Natl Parkinson Fdn Ctr Excellence, Dept Psychiat, Toronto, ON, Canada Univ Toronto Toronto ON Canada lence, Dept Psychiat, Toronto, ON, Canada Ctr Addict & Mental Hlth, Toronto, ON, Canada Ctr Addict & Mental Hlth Toronto ON Canada tal Hlth, Toronto, ON, Canada
Titolo Testata:
PARKINSONISM & RELATED DISORDERS
fascicolo: 3, volume: 7, anno: 2001,
pagine: 231 - 234
SICI:
1353-8020(200107)7:3<231:TUOPIP>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; DOPAMINE-RECEPTOR; 2 PARTS; BROMOCRIPTINE; AGONIST; MULTICENTER; CABERGOLINE; STRIATUM; EFFICACY;
Keywords:
pramipexole; Parkinson's disease; D-3 dopamine receptor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Guttman, M Univ Toronto, Natl Parkinson Fdn Ctr Excellence, Div Neurol, Dept Med, Toronto, ON, Canada Univ Toronto Toronto ON Canada Dept Med, Toronto, ON, Canada
Citazione:
M. Guttman e J. Jaskolka, "The use of pramipexole in Parkinson's disease: are its actions D-3 mediated?", PARKINS R D, 7(3), 2001, pp. 231-234

Abstract

Pramipexole is a non-ergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease (PD). It has preferential affinity for the D-3 dopamine receptor, compared to previous dopamine agonists that have higher affinity for D-2 dopamine receptors. The ultimate question is whether its efficacy is linked to its action at the D-3 dopamine site or due to its binding to D-2 dopamine receptors. There is no direct experimental evidence available to answer this question. Based on a review of the pharmacological literature, it is likely that the motor benefits of pramipexole in PD patients are due to D-2 stimulation, whereas its putative effects on mood and apathy may be related to its D3 agonist properties. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 02:44:44